002004 华邦健康
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入5,945,0320.39%11,664,67011,594,59013,232,36612,431,126
减:营业总成本5,353,288-0.32%10,758,06110,449,04411,557,13311,386,506
    其中:营业成本3,787,9921.08%7,683,8597,059,5247,874,0687,682,257
               财务费用109,607-21.38%270,037230,777207,490438,928
               资产减值损失(8,095)-31.08%(929,743)(380,091)(560,356)(138,335)
公允价值变动收益2,734-1,714.29%3,0971,199(4,837)8,516
投资收益45,605-488.67%(172,079)7,521441,485300,009
    其中:对联营企业和合营企业的投资收益28,630-174.10%(215,163)(28,839)425,722239,099
营业利润666,67518.55%(127,435)926,5111,645,0001,333,641
利润总额690,95124.67%(160,507)892,3881,622,6961,281,246
减:所得税费用141,0788.51%182,086215,456495,488361,042
净利润549,87329.62%(342,594)676,9321,127,207920,205
减:非控股权益161,41845.83%(43,604)374,810693,724252,395
股东净利润388,45623.90%(298,990)302,122433,484667,809

市场价值指针
每股收益 (元) *0.19724.15%-0.1510.1530.2190.337
每股派息 (元) *0.200----0.2200.2200.220
每股净资产 (元) *4.924-2.20%4.7165.1045.1485.106
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容